The company changes its name to Cortechs.ai to increase market awareness of its diverse AI imaging application portfolio
CorTechs Labs Inc., creators of the first volumetric MRI application for clinical use, NeuroQuant®, announced that it will begin operating under a new name, Cortechs.ai, beginning today. The rebranding strategy reflects both the evolution of the company in the AI imaging software space as well as its vision for the future.
Along with the name change, a new company logo has been revealed and a new website launched, which features the company’s focus on deep learning and machine learning as well as expanding its product lines in the oncology imaging sector. The merger with sister company HealthLytix in May of this year allowed the company to double in size and greatly increase its core product offerings.
“As part of our focus on global expansion and business development, our senior management team decided it was appropriate to rebrand our company to more specifically reflect our deep expertise and experience in developing AI tools both in and beyond neuroimaging,” said Chris Airriess, Ph.D., chief executive officer of Cortechs.ai. “I am thrilled about the introduction of our new company name, Cortechs.ai, because it allows us to better communicate our focus to our physician and industry partners.”
Although the legal name of the company will remain CorTechs Labs Inc., for marketing and branding purposes the company will now begin doing business under the new corporate name.
“2020 marks an important step in the expansion of the company’s product offerings and our team,” said Nate White, chief technology officer of Cortechs.ai. “Since bringing our flagship product, NeuroQuant, to the clinical market to aid in the assessment of dementia patients in 2006, effectively founding the volumetric imaging market, we have broadened our product offerings to include tools for the assessment of numerous other neurologic diseases and conditions that greatly help our physician partners to deliver the highest quality of care to their patients. With the HealthLytix merger, we broadened our capabilities to include AI-powered tools harnessing advanced imaging and genetics to solve problems in oncology and clinical decision support.
Over the past 12 months, Cortechs.ai has proved its status as the reigning market leader for volumetric MRI analysis, with over 1,000 clinical sites in 35 countries processing over 1,000,000 cases to date.
Cortechs.ai is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, better lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s cutting-edge brain imaging analysis provides neurologists, radiologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis of neurodegenerative and traumatic brain conditions as well as prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.